July 27, 2016
Recommended Topic Related To:

GlucaGen

"The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is adminis"...

A A A

GlucaGen




Overdosage
Contraindications

OVERDOSE

No reports of overdosage with GlucaGen® have been reported. If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

CONTRAINDICATIONS

GlucaGen® is contraindicated in patients with:

  • Known hypersensitivity to glucagon, lactose or any other constituent in GlucaGen®
  • Pheochromocytoma [see WARNINGS AND PRECAUTIONS]
  • Insulinoma [see WARNINGS AND PRECAUTIONS]
This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 2/16/2016

Overdosage
Contraindications

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Diabetes

Find tips and advances in treatment.